These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice. Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902 [TBL] [Abstract][Full Text] [Related]
23. Performance of Plasma Amyloid β, Total Tau, and Neurofilament Light Chain in the Identification of Probable Alzheimer's Disease in South China. Jiao B; Liu H; Guo L; Liao X; Zhou Y; Weng L; Xiao X; Zhou L; Wang X; Jiang Y; Yang Q; Zhu Y; Zhou L; Zhang W; Wang J; Yan X; Tang B; Shen L Front Aging Neurosci; 2021; 13():749649. PubMed ID: 34776933 [No Abstract] [Full Text] [Related]
24. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort. Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385 [TBL] [Abstract][Full Text] [Related]
25. Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease. Tzen KY; Yang SY; Chen TF; Cheng TW; Horng HE; Wen HP; Huang YY; Shiue CY; Chiu MJ ACS Chem Neurosci; 2014 Sep; 5(9):830-6. PubMed ID: 25054847 [TBL] [Abstract][Full Text] [Related]
26. Polyunsaturated Fatty Acid Composition of Cerebrospinal Fluid Fractions Shows Their Contribution to Cognitive Resilience of a Pre-symptomatic Alzheimer's Disease Cohort. Fonteh AN; Cipolla M; Chiang AJ; Edminster SP; Arakaki X; Harrington MG Front Physiol; 2020; 11():83. PubMed ID: 32116789 [TBL] [Abstract][Full Text] [Related]
27. Non-linear Character of Plasma Amyloid Beta Over the Course of Cognitive Decline in Alzheimer's Continuum. Pan FF; Huang Q; Wang Y; Wang YF; Guan YH; Xie F; Guo QH Front Aging Neurosci; 2022; 14():832700. PubMed ID: 35401142 [TBL] [Abstract][Full Text] [Related]
28. A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood. Blennow K Neurol Ther; 2017 Jul; 6(Suppl 1):15-24. PubMed ID: 28733960 [TBL] [Abstract][Full Text] [Related]
29. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. Zwan M; van Harten A; Ossenkoppele R; Bouwman F; Teunissen C; Adriaanse S; Lammertsma A; Scheltens P; van Berckel B; van der Flier W J Alzheimers Dis; 2014; 41(3):801-7. PubMed ID: 24705549 [TBL] [Abstract][Full Text] [Related]
30. Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels in Patients with Alzheimer's Disease? Travassos M; Santana I; Baldeiras I; Tsolaki M; Gkatzima O; Sermin G; Yener GG; Simonsen A; Hasselbalch SG; Kapaki E; Mara B; Cunha RA; Agostinho P; Blennow K; Zetterberg H; Mendes VM; Manadas B; de Mendon A J Alzheimers Dis; 2015; 47(4):1069-78. PubMed ID: 26401784 [TBL] [Abstract][Full Text] [Related]
31. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia. Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812 [TBL] [Abstract][Full Text] [Related]
32. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols. Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824 [TBL] [Abstract][Full Text] [Related]
33. The Validation of Multifactor Model of Plasma Aβ Jiao F; Yi F; Wang Y; Zhang S; Guo Y; Du W; Gao Y; Ren J; Zhang H; Liu L; Song H; Wang L Front Aging Neurosci; 2020; 12():212. PubMed ID: 32792940 [TBL] [Abstract][Full Text] [Related]
34. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. Palmqvist S; Insel PS; Stomrud E; Janelidze S; Zetterberg H; Brix B; Eichenlaub U; Dage JL; Chai X; Blennow K; Mattsson N; Hansson O EMBO Mol Med; 2019 Dec; 11(12):e11170. PubMed ID: 31709776 [TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal Fluid Levels of Amyloid Beta 1-43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer's Disease: A 2-Year Follow-Up Study. Lauridsen C; Sando SB; Shabnam A; Møller I; Berge G; Grøntvedt GR; Bakken IJ; Salvesen Ø; Bråthen G; White LR Front Aging Neurosci; 2016; 8():30. PubMed ID: 26973507 [TBL] [Abstract][Full Text] [Related]
36. Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease. Li WW; Shen YY; Tian DY; Bu XL; Zeng F; Liu YH; Chen Y; Yao XQ; Li HY; Chen DW; Zhou FY; Yang H; Li QM; Bao WQ; Guan YH; Zhou HD; Jin RB; Wang YJ J Alzheimers Dis; 2019; 69(1):169-178. PubMed ID: 30958377 [TBL] [Abstract][Full Text] [Related]
37. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Palmqvist S; Zetterberg H; Mattsson N; Johansson P; ; Minthon L; Blennow K; Olsson M; Hansson O; Neurology; 2015 Oct; 85(14):1240-9. PubMed ID: 26354982 [TBL] [Abstract][Full Text] [Related]
38. Idiopathic normal pressure hydrocephalus has a different cerebrospinal fluid biomarker profile from Alzheimer's disease. Jingami N; Asada-Utsugi M; Uemura K; Noto R; Takahashi M; Ozaki A; Kihara T; Kageyama T; Takahashi R; Shimohama S; Kinoshita A J Alzheimers Dis; 2015; 45(1):109-15. PubMed ID: 25428256 [TBL] [Abstract][Full Text] [Related]
39. Association of PTHrP levels in CSF with Alzheimer's disease biomarkers. Kushnir MM; Michno W; Rockwood AL; Blennow K; Strathmann FG; Hanrieder J Clin Mass Spectrom; 2019 Nov; 14 Pt B():124-129. PubMed ID: 34917769 [TBL] [Abstract][Full Text] [Related]
40. Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease. Almeida RP; Schultz SA; Austin BP; Boots EA; Dowling NM; Gleason CE; Bendlin BB; Sager MA; Hermann BP; Zetterberg H; Carlsson CM; Johnson SC; Asthana S; Okonkwo OC JAMA Neurol; 2015 Jun; 72(6):699-706. PubMed ID: 25893879 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]